Sector News

Raptor Pharmaceutical Announces Management Changes

October 24, 2014
Life sciences
Raptor Pharmaceutical Corp. today announced that it has strengthened its leadership team with the hiring of two new executives: David Happel, Chief Commercial Officer, who will oversee Raptor’s global commercial operations, and Kimberly Lee, D.O., Vice President, Corporate Strategy and Communications, who will lead strategy development, investor relations and media communications.
 
Raptor also announced that Georgia Erbez, Chief Financial Officer since September 2012, will be leaving the company to pursue other opportunities. Frank Lanza has been appointed as interim Principal Financial and Accounting Officer. Mr. Lanza has served as the company’s Controller since February 2013. Raptor has initiated a process to select a new Chief Financial Officer.  
 
“We are confident that our experienced finance team, led by Frank, will continue to meet the company’s financial, accounting and reporting needs during this transition period,” said Julie Anne Smith, President and CEO-designate of Raptor Pharmaceutical.
 
Mr. Happel and Dr. Lee will report to Ms. Smith, who added: “David and Kim bring significant strengths and capabilities to our leadership team. They will lead critical functions as we expand our commercial activities into new territories and as our clinical development programs in Huntington’s disease, NASH, Leigh syndrome and other mitochondrial diseases mature. We are delighted to welcome them to Raptor.” 
 
Mr. Happel has more than 25 years of experience in the biotechnology and pharmaceutical industry, including senior executive leadership roles in global marketing, sales and commercial operations. Mr. Happel most recently served as Chief Commercial Officer of Allergen Research Corporation, where he led global commercial and corporate development. Prior to Allergen, Mr. Happel led commercial functions at Dynavax Technologies and Aerovance, Inc. Previously, Mr. Happel held senior-level leadership positions at Dr. Reddy’s Laboratories, Chiron Corporation, InterMune, Inc. and Parke-Davis/Pfizer, where he led the development and commercialization of several market-leading products, including TOBI®, for the treatment of cystic fibrosis, and Actimmune®, for the treatment of multiple orphan diseases. Mr. Happel received his B.A. in Chemistry from Indiana University and an MBA in Marketing from Indiana State University.
 
Dr. Lee brings more than 20 years of experience in the healthcare industry, predominantly as a sell-side equity research analyst covering the biotechnology sector. Most recently, she was a managing director and senior research analyst at Janney Montgomery Scott LLC, where she focused on orphan drug, oncology and women’s health companies. Prior to Janney, she held managing director roles and progressively senior research analyst positions at ThinkEquity LLC, Pacific Growth Equities (acquired by Wedbush Securities), Jefferies & Co and Stephens Inc. Dr. Lee received her B.S. in Biological Sciences from Stanford University and her D.O. from Kirksville College of Osteopathic Medicine. She is a licensed physician and member of the American Osteopathic Association as well as author of several papers published in leading scientific and clinical journals.
 
Source: Raptor Pharmaceuticals
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend